Rosuvastatin Clopidogrel Capsule

ROSUROOT-CP 20

Rosuvastatin 20 mg and Clopidogrel 75 mg Capsules

Division: DIABGLYM

Composition

Each hard gelatin capsule contains:

Rosuvastatin Calcium IP equivalent to Rosuvastatin — 20 mg

Clopidogrel Bisulphate IP equivalent to Clopidogrel — 75 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Hard gelatin oral capsule

Product Description

ROSUROOT-CP 20 is a high-intensity cardio-protective combination of Rosuvastatin 20 mg and Clopidogrel 75 mg, formulated for the prevention and long-term management of atherosclerotic cardiovascular disease, acute coronary syndrome, post-myocardial infarction care, ischemic stroke prevention, and peripheral arterial disease. This combination provides dual cardiovascular protection by aggressively reducing LDL cholesterol and preventing platelet aggregation, thereby significantly lowering the risk of recurrent cardiovascular events.

Rosuvastatin 20 mg is a high-intensity statin therapy that effectively lowers LDL cholesterol, total cholesterol, non-HDL cholesterol, and apolipoprotein B while stabilizing atherosclerotic plaques and reducing vascular inflammation. Clopidogrel 75 mg is a well-established antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation, helping prevent thrombus formation in patients with coronary artery disease and cerebrovascular disease.

ROSUROOT-CP 20 is particularly beneficial in high-risk patients with established cardiovascular disease, diabetes, hypertension, dyslipidemia, previous myocardial infarction, previous stroke, coronary stenting, or those requiring intensive lipid-lowering therapy along with long-term antiplatelet protection.

Technical Knowledge of Rosuvastatin and Clopidogrel

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, resulting in increased LDL receptor expression and enhanced clearance of circulating LDL cholesterol. It provides potent lipid lowering, plaque stabilization, anti-inflammatory effects, and endothelial protection.

Clopidogrel is a prodrug that undergoes hepatic activation and selectively inhibits the platelet P2Y12 ADP receptor. This inhibition prevents ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation and arterial thrombus formation.

The combination of high-intensity Rosuvastatin and Clopidogrel targets both lipid-mediated atherosclerosis and platelet-mediated thrombosis, offering comprehensive cardiovascular risk reduction in high-risk patients.

Mechanism of Action

Rosuvastatin reduces hepatic cholesterol synthesis, increases LDL receptor activity, lowers LDL cholesterol and total cholesterol, stabilizes atherosclerotic plaques, improves endothelial function, and reduces vascular inflammation.

Clopidogrel irreversibly inhibits the platelet P2Y12 receptor, prevents ADP-induced platelet aggregation, reduces thrombus formation, and provides sustained antiplatelet protection.

Key Benefits

High-intensity LDL cholesterol reduction

Effective prevention of platelet aggregation

Reduces the risk of recurrent myocardial infarction

Supports secondary prevention of ischemic stroke

Stabilizes atherosclerotic plaques

Provides comprehensive cardiovascular protection

Beneficial in diabetic and high-risk cardiovascular patients

Supports long-term secondary prevention strategies

Suitable for intensive cardiovascular management under medical supervision

Clinical Applications

ROSUROOT-CP 20 is commonly prescribed for coronary artery disease, acute coronary syndrome, post-myocardial infarction therapy, post-coronary stenting management, ischemic stroke prevention, transient ischemic attack prevention, peripheral arterial disease, diabetic cardiovascular disease, high-risk dyslipidemia, and secondary prevention of atherosclerotic cardiovascular events.

Facts About Rosuvastatin and Clopidogrel

Rosuvastatin 20 mg is classified as a high-intensity statin capable of producing substantial LDL cholesterol reduction and significant cardiovascular risk reduction. Clopidogrel 75 mg is one of the most extensively studied antiplatelet agents for preventing arterial thrombosis and recurrent cardiovascular events. The combination is widely used in cardiology practice for patients requiring intensive lipid lowering and long-term antiplatelet therapy.

Key Facts

High-intensity cardiovascular protection therapy

Rosuvastatin 20 mg for aggressive LDL cholesterol reduction

Clopidogrel 75 mg for effective antiplatelet protection

Reduces atherosclerotic and thrombotic cardiovascular risk

Supports long-term secondary prevention

Evidence-based cardiology combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

ROSUROOT-CP 20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, diabetes, hypertension, stroke, dyslipidemia, and post-PCI management creates strong prescription demand and long-term market potential for this combination.

Why Choose ROSUROOT-CP 20 for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin 20 mg and Clopidogrel 75 mg Capsules with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled capsule manufacturing

Blister and Alu-Alu packaging options

ROSUROOT-CP 20 from DIABGLYM combines intensive lipid lowering, effective antiplatelet therapy, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based cardiovascular combination.